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Clinical Report
Long Term Responses with Cetuximab Therapy in Glioblastoma Multiforme
ABSTRACT
Glioblastoma multiforme (GBM) is responsible for most of the deaths associated with
primary brain tumors. Standard treatment includes maximal surgical resection followed
by chemotherapy and concomitant radiotherapy. Most patients, however, recur shortly
after treatment. Second line treatment has little efficacy and the majority of patients die
soon from the disease. Recent advances in molecular biology have implicated the epidermal
growth factor receptor (EGFR) signaling pathways in the progression and resistance to
standard therapies for GBM. This has prompted the evaluation of EGFR tyrosine- kinase
inhibitors with encouraging results. Cetuximab is a monoclonal antibody targeted against
the extra cellular domain of the EGFR with activity against different tumor types, either
alone or in combination with chemotherapy and/or radiation therapy. Here we describe
three patients with recurrent, heavily pretreated, EGFR expressing GBM who responded
to treatment with single agent cetuximab.
Glioblastoma multiforme (GBM) is the most frequent primary malignant brain tumor
in adults. Current treatment includes maximal surgical resection followed by adjuvant
treatment with chemotherapy, starting with low dose followed by full dose of temozolomide
for six months, combined with radiotherapy. In a phase III trial, this strategy resulted in a
median survival of 14.6 months and a 26.5% two-year survival. However, only 10.7% of
patients remained progression free at two years, reflecting an elevated rate of recurrence1
and most patients with disease progression die shortly thereafter. New treatment strategies
are therefore urgently needed in this setting.
Recent advances in molecular biology have implicated the EGFR signaling pathways in
the progression and resistance to standard therapies in GBM.2 Overexpression of this
receptor is present in 40% of patients with GBM and preclinical models have suggested
the potential role for EGFR targeted therapies for this condition.3 In fact, the EGFR
tyrosine-kinase inhibitors gefitinib and erlotinib are being evaluated in ongoing clinical
trials in this disease. The impact of this strategy in overall survival remains, however,
unclear.4 Recent data with EGFR kinase inhibitors suggest a protein profile associated
with responsiveness to these drugs.5 However, coexpression of EGFRvIII (a pathological
variation of EGFR that lacks the extracellular domain) and PTEN are needed to effectively
predict clinical and radiological responses in progressive GBM patients. No correlation was
observed with wild-type EGFR expression. Probably, disparate results reported with EGFR
kinase inhibitors are correlated with the absence of this protein profile. In addition, GBM
progression is associated with VEGFR pathway, which is not inhibited by these small
kinase inhibitors.
Cetuximab is a monoclonal antibody that targets the extracelullar domain of the
EGFR. In preclinical studies, the agent exerts antitumor and radiosensitizing effect in
GBM. Furthermore, in intracranial GBM models, systemic administration of cetuximab
has shown to be an effective treatment.6 Furthermore, cetuximab has shown high activity
in tumors expressing EGFR and it is capable to induce VEGFR pathway inhibition.7,8
Indeed, preclinical data suggest that cetuximab binds to and internalizes EGFRvlll. This
internalization induces an 80% reduction in active forms of EGFRvIII.9 Therefore, cetuximab
therapy was a rational strategy for the treatment of tumors that express EGFR and
EGFRvIII. At the present time, there is no available clinical data of cetuximab in patients
with GBM.
A 47-year-old white male was diagnosed with GBM located at the right frontal lobe in
September 2003 after an episode of seizure treated with phenytoin and steroids. The
patient underwent complete surgical resection with residual microscopic positive mar-
gins. Surgery was followed by radiotherapy to a total of 45 Gy in four weeks and con-
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comitant treatment with temozolomide (75 mg/m2) for
five consecutive days every 28 days. This was followed
by temozolomide (200 mg/m2) for five consecutive days
every 28 days until March 2004. In July 2004 a cranial
MRI evidenced progressive disease according RECIST
criteria and irinotecan (250 mg/m2 every 15 days) was
started. After two months of treatment, the patient
condition deteriorated with worsening of a left hemi-
paresis and motor aphasia as well as radiological pro-
gression. The tumor was stained with EGFR anti-
bodies targeted against extracellular EGFR domain and
was found to be strongly positive with membranous and
cytoplasmatic patterns. In September 2004, after
informed consent was obtained, treatment with
cetuximab, loading dose of 400 mg/m2, followed by a
weekly dose of 250 mg/m2, was initiated.
After four weeks of treatment, patient symptoms
began to improve (ECOG 4 to ECOG 1). A MRI scan performed
eight weeks after treatment demonstrated a partial response in the
tumor and considerable improvement in the surrounding edema
(Fig. 1). Therefore, steroids were progressively tapered to a mainte-
nance dose of 2mg/day of dexamethasone. The patient remained
clinically and radiologically stable with weekly cetuximab until
November 2005, when clinical and radiological worsening was
detected (time to disease progression: 14 months).
Two additional patients, a 65-year-old male and a 42-year-old
female, with primary EGFR positive GBM, located respectively at
the right parietal lobe and the left occipital lobe, were consecutively
treated. Both patients underwent maximal surgical resection (more
than 90% tumoral mass), adjuvant temozolomide concomitant with
radiotherapy and second line therapy with irinotecan. Then, pro-
gressive disease was diagnosed and they were treated with the same
cetuximab schedule described above until progression. Clinical
improvement and radiological stabilization was maintained for more
than eight months (11 months and 13 months respectively). Only,
phenytoin was administered as anticonvulsivant when needed.
The principal toxicities observed in these patients were, as expected,
moderate asthenia and skin rash (grade 1-2 CTC-NCI v2.0), similar
to those described in colorectal cancer studies.10 Although
cross-reactivity with normal CNS antigens could be an inherent risk
for cetuximab in this clinical setting, no new neurological symptoms,
other than those related to the underlying disease, were observed in
these patients.
We believe that the natural history of GBM in these three patients
was clearly modified by cetuximab. Preclinical data demonstrating that
EGFR blocking is an encouraging treatment strategy for patients
with high-grade gliomas supports our results in this group of
patients. Two potential mechanisms may be involved in this
observation. First, cetuximab exerts a direct cytotoxic effect
mediated by the blocking of EGFR in in vitro and in vivo studies.6
Second, blockage of EGFR by cetuximab induces an antiangiogenic
effect inhibiting the vascular endothelial growth factor (VEGF)
secretion as a consequence of a reduction of cellular level of
hypoxia-inducible factor1-α.7,8
Several factors limit the interpretation of these data. First, and
most important, a clinical trial is required to confirm the responses
observed in these three patients. The data, however, suggest a clear
improvement in survival when compared with historical series.1,11
Second, the ability of a bulky monoclonal antibody to reach the
CNS is not known. Several reports suggest that the blood brain barrier
is presumably disrupted in patients with gadolinium-enhancing
brain tumors. Although preclinical studies show that cetuximab
crosses the blood brain barrier, it is unlikely that the cytotoxic effects
of the antibody against the glioma cells are responsible for the entire
clinical response observed.6 In this regard, other immunological
mechanisms might be implicated.12 It is well described that secondary
GBM have a better clinical course and could explain the survival
observed in our patients. In this regard, all tumor samples were
reevaluated by an expert neuro-pathologist and none of them presented
the typical features of a secondary low-grade derived GBM. Other
prognostic factors could be implicated in the evolution of our
patients. All our patients were less than 60 years old at diagnosis. A
retrospective analysis suggests a median survival of 43 weeks for this
group.13 So, we consider that this prognosis factor has little influence
in our results. Good performance status is correlated with improved
survival in patients diagnosed with GBM. However, when cetuximab
therapy was started, every patient has a bad performance status
(ECOG 3-4) and the worst biological situation (second line was
ineffective). Thus, it is questionable that performance status had any
impact over our final data. Finally, the delay between the discontinuation
of irinotecan and cetuximab initiation could be a confounding factor that
limits our results. However, we consider that the rapid worsening (two
months until progression) and the subsequent improvement of the
clinical situation when cetuximab therapy was initiated do not
support this hypothesis.
To the best of our knowledge, these are the first clinical and
radiological responses reported for cetuximab in the treatment of
human EGFR expressing GBM. In spite of these data, the effect of
cetuximab remains indeterminate in the absence of a clinical trial.
So, we have now initiated a phase II study evaluating the efficacy of
this therapy in this patient population.
Cetuximab Therapy for Glioblastoma Multiforme
Figure 1 (A.) Baseline MRI. (B.) MRI after eight weekly doses of cetuximab.
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